The Medical Letter on Drugs and Therapeutics
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Xultophy 100/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like peptide-1) receptor agonist liraglutide, for once-daily treatment of adults with type 2 diabetes inadequately controlled on basal insulin (<50 units daily) or liraglutide (≤1.8 mg daily).

Soliqua 100/33, a long-acting insulin/GLP-1 receptor agonist combination that contains insulin glargine (Lantus, and others) and lixisenatide (Adlyxin), has also recently become available in the US.1 

GLP-1 RECEPTOR AGONISTS — GLP-1 receptor agonists lower glucose levels by potentiating glucose-dependent insulin secretion, suppressing postprandial glucagon secretion, slowing gastric emptying, and promoting satiety. They lower glycated hemoglobin (A1C) by about 1-1.5%, have been associated with weight loss of 1.5-2.8 kg, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Insulin Degludec Liraglutide (Xultophy 100 3.6) for Type 2 Diabetes
Article code: 1529a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian